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Abstract 30 
Angiotensin converting enzyme (ACE) inhibitory peptides are been extensively studied 31 
as an alternative to synthetic drugs for the treatment of hypertension. Recent studies 32 
have shown that dry-cured ham is an important source of naturally generated bioactive 33 
peptides, especially showing ACE inhibitory activity. However, due to their excessive 34 
degradation by digestive and brush-border enzymes, it is not clear whether these 35 
peptides resist intestinal absorption and reach the blood stream where they may exert 36 
their antihypertensive effect. So, dDry-cured ham extracts and specific pure peptides 37 
naturally generated during the dry-curing process, showing ACE inhibitory activity, 38 
have been studied for their stability during transepithelial transport in a Caco-2 cell 39 
monolayer. The ACE inhibitory activity of transport samples was assayed, reaching the 40 
highest values in apical samples after 15 min of incubation. In basal solutions, the 41 
highest ACE inhibition was observed for peptides AAPLAP and KPVAAP after 60 min 42 
of cellular transport. However, when basal samples were four times concentrated, a 43 
considerable increased ACE inhibitory activity was observed in these peptides from 15 44 
min of incubation. Fragments generated by cellular activity were detected by using 45 
tandem mass spectrometry MStechniques, showing that AAATP, AAPLAP, and 46 
KPVAAP were hydrolysed during the transport, although KPVAAP was also absorbed 47 
intactly. This study highlights the potential of intact dry-cured ham peptides as well as 48 
their fragments to be absorbed across the intestinal epithelium and reach the blood 49 
stream to exert an antihypertensive action. 50 
 51 
 52 
Keywords: Dry-cured ham, ACE inhibitory peptides, Caco-2 cell monolayer, intestinal 53 
transport, mass spectrometry.  54 
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1. Introduction 56 
Angiotensin I converting enzyme (ACE) is a dipeptidyl carboxypeptidase which plays 57 
an essential role as a regulator of blood pressure. ACE converts angiotensin I to the 58 
potent vasoconstrictor angiotensin II, which also induces the release of aldosterone. 59 
Moreover, ACE inactivates bradykinin, which has vasodilator activity. As a result, the 60 
action of ACE on these two systems is responsible for hypertension, the most common 61 
type of cardiovascular disease (Skeggs, Kahn, & Shumway, 1956; Ondetti, Rubin, & 62 
Cushman, 1977; Unger, 2002). To exert effects on blood pressure, ACE-inhibitory 63 
compounds such as antihypertensive peptides need to resist the degradation by 64 
gastrointestinal proteases and brush border peptidases, be absorbed through the 65 
intestinal epithelium, and finally reach the bloodstream in an active form (Vermeirssen, 66 
Augustijns, Morel, Van Camp, Opsomer, & Verstraete, 2005).  67 
Spanish dry-cured ham has recently been investigated as a natural source of 68 
antihypertensive peptides, evaluating the ACE inhibitory activity of water soluble 69 
fractions of dry-cured ham extracts (Escudero, Aristoy, Nishimura, Arihara, & Toldrá, 70 
2012), and identifying some of the peptides responsible for this inhibitory effect 71 
(Escudero, Mora, Fraser, Aristoy, Arihara, & Toldrá, 2013). Moreover, Escudero, Mora, 72 
and Toldrá (2014) have recently reported that the ACE inhibitory activity of dry-cured 73 
ham peptides persists after in vitro digestion with gastric proteases, which may be due 74 
to both resistance the stability of the existing antihypertensive peptides to digestion as 75 
well asand the generation of small fragments with showing ACE inhibitory activity. 76 
Furthermore, the in vivo antihypertensive activity of dry-cured ham extracts and peptide 77 
AAATP has been studied, showing a decrease in systolic blood pressure after their oral 78 
administration to spontaneously hypertensive rats (SHR) (Escudero et al., 2012; 79 
Escudero et al., 2013). 80 
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Transport assays through Caco-2 cells, which is a cell line derived from human colon 81 
adenocarcinoma, have been established as a model for small intestinal transport of drugs 82 
and food compounds. Differentiated Caco-2 cells maintain the morphology and function 83 
of mature enterocytes and express brush border proteases peptidases and transporters 84 
and peptidases that may affect peptide stability and transport, being therefore utilised to 85 
predict the absorption in the small intestine (Hidalgo, Raub, & Borchardt, 1989; Yee, 86 
1997). In this senseregard, several studies have been focused on studying the 87 
transepithelial transport of antihypertensive peptides derived from different food 88 
products such as egg or milk in a qualitative way (Miguel, Dávalos, Manso, De la Peña, 89 
Lasunción, & López-Fandiño, 2004; Vermeirssen et al., 2005; Quirós, Dávalos, 90 
Lasunción, Ramos, & Recio, 2008; Bejjani & Wu, 2013). However, to the best of our 91 
knowledge, there are no transport studies based on peptides showing ACE inhibitory 92 
activity derived from meat or meat products. In this work, the Caco-2 cell line was used 93 
to study the brush border degradation and transepithelial transport of ACE inhibitory 94 
peptides derived from dry-cured ham. In contrast with other studies focused on the 95 
ACE-inhibitory activity of food peptides, this study investigates the ACE-inhibitory 96 
effect of dry-cured ham peptides transported through the intestinal epithelium and hence 97 
show their potential to exert an antihypertensive action in vivo. 98 
In addition, the ACE inhibitory activity of the transported peptides was measured to 99 
evaluate their final antihypertensive potential.  100 
 101 
2. Materials and methods 102 
2.1 Material and reagents 103 
Dulbeco’s Modified Eagle’s Medium (DMEM), GlutaMAX™, phosphate buffered 104 
saline (PBS), and nonessential amino acids were procured from Life Technologies 105 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
5 
 
(Ghent, Belgium), whereas fetal bovine serum was from Greiner Bio-One (Vilvoorde, 106 
Belgium). Angiotensin-converting enzyme (from rabbit lung) was purchased from 107 
Sigma Chemical Co. (St. Louis, Mo., USA), and o-aminobenzoylglycyl-p-nitro-L-108 
phenylalanyl-L-proline (Abz-Gly-p-nitro-Phe-Pro-OH) trifluoroacetate salt was from 109 
Bachem AG. (Bubendorf, Switzerland). Methanol HPLC grade was from Sharlab, S.L. 110 
(Barcelona, Spain). All other chemicals and reagents used were of analytical grade. 111 
2.2 Dry-cured ham extracts and peptides 112 
The study was done using extracts from different types of dry-cured ham. Samples M1 113 
and S1 were obtained from Spanish dry-cured hams with ten months of processing, 114 
which were submitted subjected to extraction and deproteinisation according to the 115 
methodology described by Escudero et al. (2012). In the case of sample S1, the extract 116 
was fractionated by gel filtration chromatography using a Sephadex G-25 column (2.5 × 117 
65 cm), and fractions corresponding to elution volumes from 200 to 320 mL were 118 
pooled together and lyophiliseddried. These fractions were selected because they have 119 
shown the maximum ACE inhibitory activity, reaching values of 80% of inhibition in a 120 
previous study (Escudero et al., 2012).  In addition, Designation of Origin of Teruel 121 
hams with a minimum time of ripening of fourteen months were used to obtain samples 122 
M2 and M3. Peptide extraction was done according to the method described by 123 
Escudero et al. (2014) for sample M2, while sample M3 was submitted subjected to 124 
extraction and deproteinisation following the same procedure as described above for 125 
sample M1 and S1. All dry-cured ham extracts were desalted by solid phase extraction 126 
using an Oasis
®
 hydrophilic-lipophilic balance (HLB) cartridge (35 cc, Waters, Ireland), 127 
where peptides were retained and then eluted with 50% methanol. Finally, the eluates 128 
were lyophilised for the transport experiment across Caco-2 cells. 129 
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Since dry-cured ham extract samples contain a complex mixture of peptides that 130 
difficult a detailed study, three peptides (AAATP, AAPLAP, and KPVAAP) previously 131 
identified as ACE inhibitors in dry-cured ham (Escudero et al., 2013; Escudero et al., 132 
2014) were selected. In fact, peptides AAPLAP and KPVAAP were chosen based on 133 
their potent ACE inhibition, with IC50 values of 14.38 and 12.37 μM, respectively. 134 
Whereas, AAATP (IC50 value of 100 μM) was selected for its good in vivo 135 
antihypertensive action in the SHR model (Escudero et al., 2013). These three peptides 136 
were synthetised by GenScript Corporation (Piscataway, NJ, USA) at the highest purity 137 
certified using liquid chromatography - mass spectrometry (LC-MS) LC-MS analysis 138 
for subsequent transport experiments. 139 
2.2 Caco-2 cell culture 140 
Caco-2 cells were obtained from the American Type Culture Collection (Rockville, MD, 141 
USA). Cells were grown in DMEM containing 4.5 g/L glucose, supplemented with 142 
GlutaMAX™, 10% fetal bovine serum and 1% nonessential amino acids, at 37 °ºC in a 143 
humidified atmosphere containing 10% CO2. The passage number of the cells used in 144 
this study was between 30 and 35. For transport experiments, cells were seeded at a 145 
density of 20,000 cells/well on high throughput screening (HTS) Transwell
®
-24 well 146 
permeable supports (0.4 µm pore polyester membrane, 6.5 mm inserts, 0.33 cm
2
 cell 147 
growth area; Costar, Corning, Birmingham, UK). The culture medium was replaced 148 
every 2-3 days and cells were allowed to differentiate for at least 21 days before 149 
experiments. Cell monolayer integrity was checked visually by phase-contrast 150 
microscopy, and the transepithelial electrical resistance (TEER) of Caco-2 cells of this 151 
batch assessed with an automated tissue resistance measurement system (REMS, World 152 
Precision Instruments, Hertfordshire, UK) was higher than 300 Ω*cm².  153 
2.3 Transport studies 154 
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Differentiated Caco-2 cells were gently rinsed twice with PBS and then incubated with 155 
PBS for 1 day at 37 °ºC in 10% CO2 prior to the transport assays. After removing the 156 
PBS from all wells, 1 mg/mL of the samples dissolved in PBS were was added to the 157 
apical chambers (200 µL), whereas fresh PBS was added to the basolateral chambers (1 158 
mL). A control sample, containing only PBS and no peptides, was included in the 159 
experimental setup, and samples from apical and basolateral sides were taken before (0 160 
min) and during incubation at different time points of 15, 30, and 60 min. The action of 161 
cell proteases on samples after the transport study was immediately stopped by adding 9 162 
volumes of methanol, centrifuged at 7500g for 10 min, and finally the supernatant 163 
containing the peptides was taken and dried for the following analysis. All experiments 164 
were conducted done in triplicate. 165 
2.4 ACE inhibitory activity 166 
Apical and basal samples taken from the transepithelial transport at different times were 167 
analysed for ACE inhibitory activity. For this purpose, dried apical samples were 168 
dissolved to the original volume in bidistilled water, whereas dried basal samples were 169 
first dissolved in a volume four-fold smaller than the original one to determine the ACE 170 
inhibition in concentrated samples, and then redissolved diluted to the original volume 171 
to test again. Basal samples were concentrated in order to be comparable in terms of 172 
peptide concentration with apical samples. Additionally, the ACE inhibitory activity of 173 
several synthetised fragments derived from the degradation of AAATP, AAPLAP, and 174 
KPVAAP through the cellular transport was evaluated. In all studied cases, tThe ACE 175 
inhibitory activity was measured according to the method developed by Sentandreu and 176 
Toldrá (2006), which is based on the ability of ACE to hydrolyse the internally 177 
quenched fluorescent substrate o-aminobenzoylglycyl-p-nitro-L-phenylalanyl-L-proline 178 
(Abz-Gly-Phe(NO2)-Pro). The assay was done in triplicate. ACE inhibition of samples 179 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
8 
 
is expressed showed as ACE inhibitory percentage and as IC50 value, which is the 180 
peptide concentration that inhibits 50% of ACE activity in the reaction mixture.  181 
2.5 MALDI-ToF/ToF mass spectrometry 182 
Apical and basal samples taken after the transport of peptides AAATP, AAPLAP, and 183 
KPVAAP across Caco-2 cells were analysed using matrix-assisted laser 184 
desorption/ionisation time-of-flight/time-of-flight (MALDI-ToF/ToF) mass 185 
spectrometry to determine the molecular mass of the peptide mixture and detect those 186 
possible peptides resulting from the degradation of the precursor peptides. The analysis 187 
was done in MS mode, and a total of 1 L of every sample was directly spotted on the 188 
MALDI plate and allowed to air dry. Then, 0.5 L of matrix solution (which contains 5 189 
mg/mL of α-cyano-4-hydroxycinnamic acid (HCCA; Bruker Daltonics, Germany) in 190 
0.1% TFA-ACN/H2O trifluoroacetic acid - acetonitrile/water (7:3, v/v) was spotted. The 191 
analysis was done in a 5800 MALDI ToF/ToF instrument (AB Sciex, MA, USA) in 192 
positive reflectron mode (3000 shots every position) in the range from 150 to 800 Da 193 
m/zrange; the laser intensity was manually adjusted to maximize the S/N ratio. The 194 
system was adjusted with voltages of 15 and 3 kV in the source and reflector detector, 195 
respectively. Previously, the plate model and the acquisition methods were calibrated by 196 
AB Sciex calibration mixture (1 fmol/μL des-Arg1-Bradykinin; 2 fmol/μL Angiotensin 197 
I; 1.3 fmol/μL Glu1-Fibrinopeptide B; 2 fmol/μL Adrenocorticotropic hormone 198 
(ACTH) (1–17 clip); 5 fmol/μL ACTH (18–39 clip); and 3 fmol/μL ACTH (7–38 clip)) 199 
in 13 positions.  200 
The candidate precursors were then selected for every position in the MS/MS 201 
(ToF/ToF) analysis in order to confirm their presence. In this senseregard, ten of the 202 
most intense precursors according to the threshold criteria minimum signal-to-noise: 10, 203 
minimum cluster area: 500, maximum precursor gap: 200 ppm, and maximum fraction 204 
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gap: 4, were selected. The MS/MS method was calibrated using Angiotensin I MS/MS 205 
spectra in 13 positions, and data was acquired using the default 1kV MS/MS method. 206 
Manual analysis of data was done using mMass – Open Source Mass Spectrometry Tool 207 
Software v.5.5 (http://www.mmass.org) (Strohalm, Kavan, Novák, Volný, & Havlíček, 208 
2010). The search of peptide sequences previously identified showing ACE inhibitory 209 
activity was done using BIOPEP database 210 
(http://www.uwm.edu.pl/biochemia/index.php/en/biopep).  211 
2.6 Statistical analysis 212 
Statistical analysis was done using Statgraphics Centurion XVI software. One-way 213 
analysis of variance (ANOVA) was performed and the mean and standard deviation 214 
were reported. Fisher’s multiple range test was carried out to analyse significant 215 
differences among mean values at p < 0.05. 216 
 217 
3. Results and discussion 218 
3.1 Transepithelial transport of peptides across Caco-2 cell monolayer 219 
In order to simplify the study of dry-cured ham extracts which contain a complex 220 
mixture of thousands of peptides, the apical to basal flux transport in Caco-2 cell 221 
monolayers was mainly studied with the purified peptides (AAATP, AAPLAP, and 222 
KPVAAP). For that, 1 mg/mL of every sample was added to the apical side, and 223 
samples were taken from both apical and basal compartments at different times: 0, 15, 224 
30, and 60 min. 225 
The evolution of peptides AAATP, AAPLAP, and KPVAAP during their transcellular 226 
transport was then monitored by using MALDI-ToF mass spectrometry to determine the 227 
profile of peptides according to their molecular masses. As illustrated in Figure 1, there 228 
are more and smaller peptides in the samples taken from the basal sides than those of 229 
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the apical ones, suggesting a partial degradation of the precursor peptides into smaller 230 
fragments by the action of cell peptidases as well asand their absorption through the 231 
Caco-2 cell monolayer. The size, amino acid sequence, charge, hydrogen-bonding 232 
capacity, non-enzymatic glycosylation, and hydrophobicity of peptides are critical in 233 
determining their susceptibility to peptidases and their permeability across the intestinal 234 
epithelium (Pauletti, Okumu, & Borchardt, 1997; Shimizu, Tsunogai, & Arai, 1997; 235 
Artursson, Palm, & Luthman, 2001). 236 
3.2 ACE inhibitory activity of samples taken from transport assays 237 
Dry-cured ham extracts and peptide solutions taken from the apical and basal 238 
compartments at different transport times were analysed for ACE inhibitory activity , 239 
directly after sampling and in basal samples also after concentrating four times (Figure 240 
2). In the case of dry-cured ham extracts, sSamples taken from the apical side showed 241 
high ACE inhibition, generally reaching the maximum values at 15 min of cellular 242 
transport except for sample S1, which presented slightly higher ACE inhibition before 243 
incubation than during the cellular assay. in both types of samples, and with values very 244 
close to 100% inhibition for the purified peptides. These high inhibition values at 15 245 
min of the transport may be due to a strong action of cell peptidases on these peptides at 246 
this time, whereby the modification of the peptide structure may affect its biological 247 
activity and peptide fragments released can show even a higher degree of ACE 248 
inhibitory activity compared toin comparison with the precursor peptides (Miguel, 249 
Recio, Gómez-Ruiz, Ramos, & López-Fandiño, 2004). In fact, In the case of dry-cured 250 
ham samples, samples M1 and S1 showed similar inhibition results even though sample 251 
S1 contained only the fractions which showing the highest ACE inhibitory activity. 252 
Meanwhile, the activity decreases more significantly after 30 min of transport for 253 
samples M2 and M3, which come from dry-cured hams with longer curing process. The 254 
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ACE inhibition activity for sample M2 before the transport assay was very low (with a 255 
value of 4.5%), which is in agreement with a previous study (Escudero et al., 2014), and 256 
which that is probably due owing to this sample has not been deproteinised compared 257 
toin comparison with sample M3. Additionally, sample M2 did not show any ACE 258 
inhibitory activity in the apical side after 60 min of cellular transport, indicating that 259 
inhibitory peptides were either completely hydrolysed or transported to the basal side. 260 
On the other hand, little to no ACE inhibition was detected in the basal samples, so For 261 
this reason, all basal samplesthey were concentrated four times to check if samples may 262 
show ACE inhibitory activity at higher concentration. Under these conditions, dry-cured 263 
ham extract samples showed activity although to a varying degree, obtaining values 264 
around 30-40% at 15 min of transport and then decreasing during time. 265 
With regard to purified peptides, Figure 2 evidences ACE inhibition values very close 266 
to 100% in apical samples at 15 min of the transport. On the other hand, little to no 267 
ACE inhibition was detected iIn the basal samples, except significant results were only 268 
found for peptides AAPLAP and KPVAAP after 60 min of transport, whereby ACE 269 
inhibitory activity reached values of 42% and 30%, respectively. However, for purified 270 
peptidesin the case of concentrated basal samples, the ACE inhibitory activity of 271 
peptides AAATP and AAPLAP increased during incubation, reaching values up to 30% 272 
for AAATP and 70% for AAPLAP at 60 min of the assay. HAlso high percentages of 273 
inhibition (around 65%) were also observed for KPVAAP after 15 and 60 min of 274 
cellular transport.  275 
These results indicate that some peptides as well asalong with small derived fragments 276 
could be absorbed, maintaining their ACE inhibitory activity after cellular transport 277 
although at low concentration in non-concentrated basal samples (Figure 2). Moreover, 278 
synergic effects between antihypertensive peptides could explain higher values of ACE 279 
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inhibition for peptide mixtures in comparison to the individual activity of individual 280 
peptides. In addition, it should be stressed highlighted that the concentration of peptides 281 
in the basal and concentrated basal samples does not show a linear but exponential 282 
response when ACE activity is plotted against the concentration of an ACE inhibitory 283 
peptides, as previously described by Sentandreu and Toldrá,  (2006). 284 
Because angiotensin I converting enzyme is present in the brush border contributing to 285 
hydrolysis of peptides (Yoshioka, Erickson, Woodley, Gulli, Guan, & Kim, 1987), 286 
control samples containing only the Caco-2 cells and PBS were also analysed for ACE 287 
inhibitory activity, showing non-significant effects (data not shown). Nevertheless, 288 
these values were taken into account for determining the percentage of ACE inhibition 289 
of the samples. 290 
3.3 Peptide degradation by epithelial peptidases 291 
As dry-cured ham samples contain a very complex mixture of peptides, only the 292 
degradation of the purified peptides on the brush-border side was evaluated by MS-293 
based techniques in order to detect those peptides that were transcellularly transported. 294 
Table 1 shows the peptide sequences detected by MALDI-ToF/ToF MS in the apical 295 
and basal compartments at the different assayed times.  296 
The analysis revealed the degradation of the intact peptide AAATP after 15 min of 297 
transport with and the generation of smaller sized peptides, some of which can could 298 
cross the intestinal barrier up to the basal side. On the other hand, AAPLAP was 299 
detected in the apical chamber throughout the experiment, but analysis of the basal 300 
solutions showed that it was not transported intact. In fact, several shorter fragments 301 
were also detected in the apical and basal solutions, suggesting its partial degradation by 302 
brush border peptidases. Furthermore, peptide KPVAAP was detected up to 60 min of 303 
transport in both apical and basal samples, indicating that its chemical and structural 304 
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properties allow it to be absorbed intact through the Caco-2 monolayer. However, it was 305 
also susceptible to peptidases and different derived fragments were also detected in 306 
apical and basal solutions. In this senseregard, among all the fragments detected in 307 
either apical or basal samples, several of them were previously reported as ACE 308 
inhibitory peptides (Table 1 of Supplementary material2), being LAP and VAA those 309 
with the lowest IC50 values. The remaining peptides detected at different times of 310 
incubation as shown in Table 1 (AATP, ATP, AAAT, APLA, PLAP, AAPL, VAAP, 311 
KPV, AAA, and VA) were synthetised and assayed for the in vitro ACE inhibitory 312 
activity in order to calculate their IC50 values (Table 32). These results highlight the 313 
potent inhibition of fragment VAAP resulting from KPVAAP degradation, and PLAP 314 
from AAPLAP, which showed IC50 values of 16.75 and 76.5 µM, respectively. This fact 315 
could be explained by the presence of hydrophobic amino acids such as proline and 316 
alanine close to the C-terminal position of the peptides that positively influence the 317 
binding to ACE (Rohrbach, Williams, & Rolstad, 1981; Majumder, & Wu, 2009). 318 
Hence, the ACE inhibitory activity shown by the peptide fragments could also explain 319 
the inhibitory activity found previously in apical and basal samples (see Figure 2-b), 320 
suggesting that those fragments transported across the monolayer could also reach the 321 
blood stream to exert an antihypertensive activity. As such, brush border peptidases 322 
play a key role in the formation and degradation of bioactive peptides and therefore, in 323 
their bioavailability and physiological effect (Pihlanto-Leppälä, 2000; Vermeirssen, et 324 
al., 2005; Miguel & Aleixandre, 2006).  325 
The study done by Escudero et al. (2013) showed in vivo ACE inhibitory activity for the 326 
peptide AAATP, although according to the present study it is not absorbed intact 327 
through the intestinal barrier (Table 1). These results suggest that either the fragments 328 
derived from its degradation are responsible for the decrease in blood pressure in the 329 
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SHR model, or AAATP may exert antihypertensive activity through the interaction with 330 
receptors expressed in the gastrointestinal epithelia (Yamada, Matoba, Usiu, Onishi, & 331 
Yoshikawa, 2002), thereby inducing other mechanisms of blood pressure regulation 332 
such as through nitric oxide or endothelin production (Lifton, Gharavi, & Geller, et al., 333 
2001).   334 
The stability of peptides to enzymatic hydrolysis and absorption processes determine 335 
their bioavailability and bioactivity, being the main cause of differences found between 336 
in vitro and in vivo assays (Pihlanto-Leppälä, 2000; Vermeirssen, Van Camp, & 337 
Verstraete , 2004; Bejjani, & Wu, 2013). In fact, the amount of peptides absorbed in 338 
vivo could be higher than in vitro assays when Caco-2 cells are used as models, due 339 
owing to the lower expression of some intestinal transporters and tighter junctions in 340 
Caco-2 cell monolayers compared toin comparison with in vivo intestinal tissues 341 
(Lennernäs, Palm, Fagerholm, & Artursson, 1996; Boisset, Botham, Haegele, Lenfant, 342 
& Pachot, 2000; Vermeirssen et al., 2005). Nevertheless, this study suggests a beneficial 343 
impact of dry-cured ham peptides towards blood pressure due to their potential to exert 344 
an in vivo antihypertensive action. 345 
 346 
4. Conclusions 347 
Previous studies reported the ACE inhibitory activity of some dry-cured ham peptides 348 
and their stability to in vitro digestion. However, antihypertensive peptides need to 349 
resist the complete hydrolysis by brush-border peptidases and be absorbed actively 350 
across the intestinal epithelium to exert their activity. The transepithelial transport 351 
through a Caco-2 cell monolayer has been studied in dry-cured ham extracts and 352 
purified peptides, evaluating the degradation of peptides by mass spectrometry. Results 353 
showed that peptides AAATP, AAPLAP, and KPVAAP are degraded throughout the 354 
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transport assay, although KPVAAP can also be absorbed intact through the intestinal 355 
barrier. Moreover, this study evidences for the first time the absorption and generation 356 
of ACE inhibitory peptide fragments originating from dry-cured ham by the Caco-2 cell 357 
line. The antihypertensive action of the peptides or small fragments derived as well as 358 
the synergic effect between them could explain the ACE inhibitory results obtained in 359 
apical and basal samples, suggesting that dry-cured ham peptides could reach the 360 
circulatory system to exert an antihypertensive action. 361 
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 480 
 481 
FIGURE CAPTIONS 482 
Figure 1.  MALDI-ToF mass spectra of samples taken from the transepithelial transport  483 
(apical and basal sides) through Caco-2 cell monolayer at different times (0, 15, 30, 60 484 
min) after adding the purified peptides a) AAATP, b) AAPLAP, and c) KPVAAP. 485 
Figure 2.  ACE inhibitory activity (%) observed in the apical, basal, and four times 486 
concentrated basal compartments obtained from the cellular transport after the 487 
application of a) dry-cured ham extracts and b) purified peptides. DifferentBar letters in 488 
indicate significant differences at p < 0.05 (n=3) between different times of the cellular 489 
transport (0, 15, 30, 60 min) in each compartment and sample ( a = apical; a = basal 4x; 490 
a = basal). 491 
sample and compartment indicate significant differences at p < 0.05 (n=3). 492 
Table 1. Peptide sequences detected by using MALDI-ToF/ToF MS in the cellular transport assay.
Precursor Peptide Monoisotopic     Apical  –  times (min)
c
  Basal –  times (min)
d
peptide fragments
a  mass (Da)b 0 15 30 60 15 30
AAATP* 429.22 x x
AATP 358.19 x x x
AAAT 332.17 x
ATP 287.15 x x x
AAA 231.12 x
AAPLAP* 538.31 x x x x
PLAP 396.24 x x x
APLA 370.44 x x
AAPL 370.22 x x
PL * 228.15 x x
LA * 202.13
KPVAAP* 581.35 x x x x x x
VAAP 356.21 x x x
KPV 342.23 x x x
KP* 243.16 x x
VA 188.12 x x x x x
AP* 186.10 x x x
*Sequences previously identified showing ACE inhibitory activity according to BIOPEP database (see Table 1 of Supplementary material).
a Possible fragments derived from the degradation of the precursor peptide.
b Monoisotopic molecular mass in Daltons of the matched peptide.
c Peptides detected in the apical compartment at different transport times.
d Peptides detected in the basal compartment at different transport times.
Table 1
Table 2. ACE inhibitory activity (IC50) of synthetic peptides.
Peptides IC50 (µM)
VAAP 16.75
PLAP 76.50
AAA 111.47
AATP 300.74
ATP 406.56
AAAT 513.65
VA 607.96
KPV > 1000
AAPL > 1000
APLA > 1000
Table 2
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Supplementary Table 1. Peptide sequences previously identified as ACE inhibitors reported by other authors.
Peptides IC50 (µM)
KPVAAP 12.37
AAPLAP 14.38
KP 22
AAATP 100
AP 230
LA 310
PL 337.32
Supplementary material
